(Q50584849)

16 March 2018

title

Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. (English)

1 reference

16 March 2018

1 reference

Hugo R Rosen

1

1 reference

16 March 2018

John G McHutchison

2

1 reference

16 March 2018

Andrew J Conrad

3

1 reference

16 March 2018

Jennifer J Lentz

4

1 reference

16 March 2018

Gail Marousek

5

1 reference

16 March 2018

Steven L Rose

6

1 reference

16 March 2018

Atif Zaman

7

1 reference

16 March 2018

Kent Taylor

8

1 reference

16 March 2018

Sunwen Chou

9

1 reference

16 March 2018

language of work or name

English

0 references

publication date

1 March 2002

1 reference

16 March 2018

The American Journal of Gastroenterology

published in

1 reference

16 March 2018

volume

97

1 reference

16 March 2018

issue

3

1 reference

16 March 2018

page(s)

714-720

1 reference

16 March 2018

Genetics of tumour necrosis factor (TNF) in autoimmune liver diseases: red hot or red herring?

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05552.X

The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05552.X

Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05552.X

Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05552.X

Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05552.X

An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05552.X

Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05552.X

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05552.X

Chronic viral hepatitis and the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05552.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05552.X

Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05552.X

A new TNFA promoter allele identified in South American Blacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05552.X

Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05552.X

10.1111/J.1572-0241.2002.05552.X

21 January 2018

Identifiers

DOI

1 reference

16 March 2018

1 reference

16 March 2018